Detailed imaging and genetic analysis reveal a secondaryBRAFL505Hresistance mutation and extensive intrapatient heterogeneity in metastaticBRAFmutant melanoma patients treated with vemurafenib
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Detailed imaging and genetic analysis reveal a secondaryBRAFL505Hresistance mutation and extensive intrapatient heterogeneity in metastaticBRAFmutant melanoma patients treated with vemurafenib
Authors
Keywords
-
Journal
Pigment Cell & Melanoma Research
Volume 28, Issue 3, Pages 318-323
Publisher
Wiley
Online
2014-12-17
DOI
10.1111/pcmr.12347
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
- (2014) Alexander M. Menzies et al. PLoS One
- Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
- (2013) E. Romano et al. CLINICAL CANCER RESEARCH
- Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection
- (2013) S.H. Tirumani et al. EJSO
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain
- (2013) Timothy R. Wagenaar et al. Pigment Cell & Melanoma Research
- Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors
- (2013) Jaehyuk Choi et al. Pigment Cell & Melanoma Research
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Semi-automatic software increases CT measurement accuracy but not response classification of colorectal liver metastases after chemotherapy
- (2012) Charlotte S. van Kessel et al. EUROPEAN JOURNAL OF RADIOLOGY
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
- (2012) Li Ding et al. NATURE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
- (2012) Gaia Schiavon et al. PLoS One
- Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment
- (2011) J. S. Vermaat et al. CLINICAL CANCER RESEARCH
- Identification of genetic disparity between primary and metastatic melanoma in human patients
- (2011) Alexander Swoboda et al. GENES CHROMOSOMES & CANCER
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- The patterns and dynamics of genomic instability in metastatic pancreatic cancer
- (2010) Peter J. Campbell et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis
- (2009) Nikolas H. Stoecklein et al. INTERNATIONAL JOURNAL OF CANCER
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
- (2008) Toshirou Nishida et al. CANCER SCIENCE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started